References
- Talbot K. Motor neuron disease. Postgrad Med J. 2002; 78:513–9.
- Gordon PH. Amyotrophic Lateral Sclerosis: An update for 2013. Clinical Features, Pathophysiology, Management and Therapeutic Trials. Aging Dis. 2013;4:295–310.
- Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, et al. The epidemiology of ALS and the role of population based registries. Biochim Biophys. Acta BBA – Mol Basis Dis. 2006;1762:1150–7.
- Doyle P, Brown A, Beral V, Reeves G, Green J. Incidence of and risk factors for motor neuron disease in UK females: a prospective study. BMC Neurol. 2012;12:25.
- Marin B, Couratier P, Preux P-M, Logroscino G. Can mortality data be used to estimate amyotrophic lateral sclerosis incidence?Neuroepidemiology. 2011;36:29–38.
- Alonso V, Villaverde-Hueso A, Hens MJ, Morales-Piga A, Abaitua I, de la Paz MP. Increase in motor neuron disease mortality in Spain: temporal and geographical analysis (1990–2005). Amyotroph Lateral Scler. 2011;12:192–8.
- Spanish Rare Diseases Registries Research Network- SpainRDR [cited 2013 Nov 15]. Available from: https://spainrdr.isciii.es/en.
- Rivero A. The Minimum Data Set in NHS: Beginnings and current development]. Fuentes Estadísticas. 2000;49:18–9.
- Preux P-M, Druet-Cabanac M, Couratier P, Debrock C, Truong T, Marcharia W, et al. Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. J Clin Epidemiol. 2000; 53:1025–9.
- Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy Amst Neth. 2010;97:173–9.
- Dodge JA, Chigladze T, Donadieu J, Grossman Z, Ramos F, Serlicorni A, et al. The importance of rare diseases: from the gene to society. Arch Dis Child. 2011;96:791–2.
- Alonso V, Villaverde-Hueso A, Hens M, Morales-Piga A, Abaitua I, Posada de la Paz M. Public health research on rare diseases. Georgian Med News. 2011;4:11–6.
- Nagel G, Unal H, Rosenbohm A, Ludolph AC, Rothenbacher D, ALS Registry Study Group. Implementation of a population based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) registry Swabia. BMC Neurol. 2013;13:22.
- Fang F, Al-Chalabi A, Ronnevi L-O, Turner MR, Wirdefeldt K, Kamel F, et al. Amyotrophic lateral sclerosis and cancer: a register based study in Sweden. Amyotroph Lateral Scler Frontal Lobar* Degener. 2013;14:362–8.
- Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995 to 2010. PloS One. 2013;8:e74733.
- Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, Janssen A, et al. The association between ALS and population density: a population based study. Amyotrophic Lateral Sclerosis Official Publication, World Federation Research Group Motor Neuron Disorders. 2010;11:435–8.
- Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population?Neurology. 2011;77:1432–7.
- Kurian KM, Forbes RB, Colville S, Swingler RJ. Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. J Neurol Neurosurg Psychiatry. 2009;80:84–7.
- Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, et al. The epidemiology of ALS and the role of population based registries. Biochim Biophys Acta. 2006; 1762:1150–7.
- Maxwell R, Wells C, Verne J. Under-reporting of progressive supranuclear palsy. Lancet. 2010;376:2072.
- Yeo L, Lynch C, Hardiman O. Validating population based registers for ALS: how accurate is death certification?J Neurol. 2010;257:1235–9.
- Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.